A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Hypothalamic Obesity, Prader-Willi Syndrome, PWS
In brief
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment
Key facts
- Study ID
- NCT06239116
- Run by
- Rhythm Pharmaceuticals, Inc.
- People needed
- 150
- Starts
- 2024-03-05
- Expected to finish
- 2028-11-01
- Last updated by the study team
- 2025-12-22
Who can join
Age: 12 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Brigham and Women's Hospital (Part C and Part D) — Boston, Massachusetts, United States (enrolling)
- Ann and Robert H. Lurie Children's Hospital of Chicago (Part C and Part D) — Chicago, Illinois, United States (enrolling)
- Boston Children's Hospital (Part C only) — Boston, Massachusetts, United States (enrolling)
- UAB Pediatric Endocrinology (Part C and Part D) — Birmingham, Alabama, United States (enrolling)
- Vanderbilt University Medical Center (Part C only) — Nashville, Tennessee, United States (enrolling)
- University of Utah Pediatric Endocrine Clinic (Part C and Part D) — Salt Lake City, Utah, United States (enrolling)
- Worldwide Clinical Trials (Part A and Part B) — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.